Fig. 1
From: Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer
Chimeric Antigen Receptor (CAR) T cell Therapy. The extracellular domain of CARs uses the scFv, which is derived from the variable region of antibodies, to identify tumor antigens on the surface of tumor cells. A transmembrane (TM) domain connects the extracellular and intracellular regions of CARs, as well as one or more costimulatory domains that cause a longer T-cell activation and cytokine-mediated killing of tumor cells